International Reviews of Immunology最新文献_第6页

Molecular mechanisms of ferroptosis and their role in inflammation. 铁下垂的分子机制及其在炎症中的作用。

IF 5 4区医学

International Reviews of Immunology Pub Date : 2023-01-01 DOI: 10.1080/08830185.2021.2016739

Feng Wang, Jingya He, Ruxiao Xing, Tong Sha, Bin Sun

引用次数: 15

Host-directed antileishmanial interventions: Harvesting unripe fruits to reach fruition. 宿主导向的抗利什曼干预:收获未成熟的果实以达到结果。

IF 5 4区医学

International Reviews of Immunology Pub Date : 2023-01-01 DOI: 10.1080/08830185.2022.2047670

Anuradha Seth, Susanta Kar

{"title":"Host-directed antileishmanial interventions: Harvesting unripe fruits to reach fruition.","authors":"Anuradha Seth, Susanta Kar","doi":"10.1080/08830185.2022.2047670","DOIUrl":"https://doi.org/10.1080/08830185.2022.2047670","url":null,"abstract":"Leishmaniasis is an exemplary paradigm of immune evasion, fraught with the perils of limited clinical assistance, escalating costs of treatment and made worse with the lack of suitable vaccine. While drugs remain central to large-scale disease control, the growing emergence of parasite resistance necessitates the need for combination therapy involving host-directed immunological agents. Also, since prolonged disease progression is associated with strong immune suppression of the host, augmentation of host immunity via restoration of the immunoregulatory circuit involving antigen-presenting cells and T-cells, activation of macrophage function and/or CD4+ T helper 1 cell differentiation may serve as an ideal approach to resolve severe cases of leishmaniasis. As such, therapies that embody a synergistic approach that involve direct killing of the parasite in addition to elevating host immunity are likely to pave the way for widespread elimination of leishmaniasis in the future. With this review, we aim to recapitulate the various immunotherapeutic agents found to hold promise in antileishmanial treatment both in vitro and in vivo. These include parasite-specific antigens, dendritic cell-targeted therapy, recombinant inhibitors of various components intrinsic to immune cell signaling and agonists or antagonists to immune cells and cytokines. We also summarize their abilities to direct therapeutic skewing of the host cell-immune response and review their potential to combat the disease either alone, or as adjunct modalities.","PeriodicalId":14333,"journal":{"name":"International Reviews of Immunology","volume":"42 3","pages":"217-236"},"PeriodicalIF":5.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9807567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. SARS-CoV-2变体和COVID-19疫苗:当前挑战和未来战略

IF 5 4区医学

International Reviews of Immunology Pub Date : 2023-01-01 Epub Date: 2022-05-28 DOI: 10.1080/08830185.2022.2079642

Wenping Gong, Seppo Parkkila, Xueqiong Wu, Ashok Aspatwar

{"title":"SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.","authors":"Wenping Gong, Seppo Parkkila, Xueqiong Wu, Ashok Aspatwar","doi":"10.1080/08830185.2022.2079642","DOIUrl":"10.1080/08830185.2022.2079642","url":null,"abstract":"The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global threat. Despite strict control measures implemented worldwide and immunization using novel vaccines, the pandemic continues to rage due to emergence of several variants of SARS-CoV-2 with increased transmission and immune escape. The rapid spread of variants of concern (VOC) in the recent past has created a massive challenge for the control of COVID-19 pandemic via the currently used vaccines. Vaccines that are safe and effective against the current and future variants of SARS-CoV-2 are essential in controlling the COVID-19 pandemic. Rapid production and massive rollout of next-generation vaccines against the variants are key steps to control the COVID-19 pandemic and to help us return to normality. Coordinated surveillance of SARS-CoV-2, rapid redesign of new vaccines and extensive vaccination are needed to counter the current SARS-CoV-2 variants and prevent the emergence of new variants. In this article, we review the latest information on the VOCs and variants of interest (VOIs) and present the information on the clinical trials that are underway on evaluating the effectiveness of COVID-19 vaccines on VOCs. We also discuss the current challenges posed by the VOCs in controlling the COVID-19 pandemic and future strategies to overcome the threat posed by the highly virulent and rapidly transmissible variants of SARS-CoV2.","PeriodicalId":14333,"journal":{"name":"International Reviews of Immunology","volume":"1 1","pages":"393-414"},"PeriodicalIF":5.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46254001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 23

Regulatory Effects of Clock and Bmal1 on Circadian Rhythmic TLR Expression. 时钟和Bmal1对TLR昼夜节律表达的调控作用。

IF 5 4区医学

International Reviews of Immunology Pub Date : 2023-01-01 DOI: 10.1080/08830185.2021.1931170

Xu-Li Fan, Ying Song, Dong-Xu Qin, Pei-Yao Lin

引用次数: 6

Pyroptosis in neurodegenerative diseases: What lies beneath the tip of the iceberg? 神经退行性疾病中的焦亡:冰山一角下隐藏着什么?

IF 5 4区医学

International Reviews of Immunology Pub Date : 2023-01-01 DOI: 10.1080/08830185.2022.2052064

Mengli Yue, Li Xiao, Rui Yan, Xinyi Li, Wei Yang

引用次数: 2

Disparities in positive results and dissemination of randomized controlled trials in immuno-oncology. 免疫肿瘤学随机对照试验阳性结果的差异和传播。

IF 5 4区医学

International Reviews of Immunology Pub Date : 2023-01-01 DOI: 10.1080/08830185.2022.2088744

Cheng Xu, Shu Zhang, Guang-Li Zhu, Kai-Bin Yang, Yuan Zhang, Yan-Ping Mao, Ling-Long Tang, Qing Liu, Ying Huang, Jun Ma

{"title":"Disparities in positive results and dissemination of randomized controlled trials in immuno-oncology.","authors":"Cheng Xu, Shu Zhang, Guang-Li Zhu, Kai-Bin Yang, Yuan Zhang, Yan-Ping Mao, Ling-Long Tang, Qing Liu, Ying Huang, Jun Ma","doi":"10.1080/08830185.2022.2088744","DOIUrl":"https://doi.org/10.1080/08830185.2022.2088744","url":null,"abstract":"Background: This cross-sectional and longitudinal analysis aimed to demonstrate the disparities in positive results and dissemination patterns of randomized controlled trials (RCTs) in global immuno-oncology (IO).Methods: Phase II-IV RCTs with results reported by article publications registered on ClinicalTrials.gov in 2007-2018 studying immune checkpoint inhibitors (ICIs), adoptive cell transfer, cancer vaccines, and immune modulators were included.Results: Twenty-eight percent of trials were positive (72 of 258), most of which were pharma-sponsored and focused on ICI and multiple IO therapies in lung cancer, melanoma, and multiple cancer types. The recent period of trial start year, upfront registration, large sample size, high strictness score on corticosteroid/infection-related criteria, and survival endpoints were associated with positive results. Trials from Mainland China had a faster publication timeline of positive results but lacked study diversity or full reporting of negative results compared with US and multinational trials. Compared with phase II trials, phase III-IV trials had a higher average proportion of positive results (28.9% vs. 22.2%) and a more stable change over the past decade (23.65% vs. 49.24%). Positive trials yielded more secondary manuscripts (10 vs. 4), a shorter publication process of approximately two years (P < 0.001), and a superiority in the dissemination of journals with an h-index >90 (P < 0.001) compared with negative trials.Conclusion: Disparities in positive result dissemination are widespread in IO RCTs and affected by trial features. We proposed improvements in upfront registration, procedural integrity, and adequate inclusion of rival trials reporting negative results within the earlier two years in future reviews.","PeriodicalId":14333,"journal":{"name":"International Reviews of Immunology","volume":"42 2","pages":"91-100"},"PeriodicalIF":5.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9825036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dysregulated translational factors and epigenetic regulations orchestrate in B cells contributing to autoimmune diseases. 失调的翻译因子和表观遗传调控在B细胞中协调促进自身免疫性疾病。

IF 5 4区医学

International Reviews of Immunology Pub Date : 2023-01-01 DOI: 10.1080/08830185.2021.1964498

Ming Yang, Ping Yi, Jiao Jiang, Ming Zhao, Haijing Wu, Qianjin Lu

{"title":"Dysregulated translational factors and epigenetic regulations orchestrate in B cells contributing to autoimmune diseases.","authors":"Ming Yang, Ping Yi, Jiao Jiang, Ming Zhao, Haijing Wu, Qianjin Lu","doi":"10.1080/08830185.2021.1964498","DOIUrl":"https://doi.org/10.1080/08830185.2021.1964498","url":null,"abstract":"B cells play a crucial role in antigen presentation, antibody production and pro-/anti-inflammatory cytokine secretion in adaptive immunity. Several translational factors including transcription factors and cytokines participate in the regulation of B cell development, with the cooperation of epigenetic regulations. Autoimmune diseases are generally characterized with autoreactive B cells and high-level pathogenic autoantibodies. The success of B cell depletion therapy in mouse model and clinical trials has proven the role of B cells in pathogenesis of autoimmune diseases. The failure of B cell tolerance in immune checkpoints results in accumulated autoreactive naïve B (BN) cells with aberrant B cell receptor signaling and dysregulated B cell response, contributing to self-antibody-mediated autoimmune reaction. Dysregulation of translational factors and epigenetic alterations in B cells has been demonstrated to correlate with aberrant B cell compartment in autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, primary Sjögren's syndrome, multiple sclerosis, diabetes mellitus and pemphigus. This review is intended to summarize the interaction of translational factors and epigenetic regulations that are involved with development and differentiation of B cells, and the mechanism of dysregulation in the pathogenesis of autoimmune diseases.","PeriodicalId":14333,"journal":{"name":"International Reviews of Immunology","volume":"42 1","pages":"1-25"},"PeriodicalIF":5.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9459169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

The role of sialic acid-binding immunoglobulin-like-lectin-1 (siglec-1) in immunology and infectious disease. 唾液酸结合免疫球蛋白样凝集素-1 (siglec1)在免疫学和感染性疾病中的作用。

IF 5 4区医学

International Reviews of Immunology Pub Date : 2023-01-01 DOI: 10.1080/08830185.2021.1931171

Shane Prenzler, Santosh Rudrawar, Mario Waespy, Sørge Kelm, Shailendra Anoopkumar-Dukie, Thomas Haselhorst

{"title":"The role of sialic acid-binding immunoglobulin-like-lectin-1 (siglec-1) in immunology and infectious disease.","authors":"Shane Prenzler, Santosh Rudrawar, Mario Waespy, Sørge Kelm, Shailendra Anoopkumar-Dukie, Thomas Haselhorst","doi":"10.1080/08830185.2021.1931171","DOIUrl":"https://doi.org/10.1080/08830185.2021.1931171","url":null,"abstract":"Siglec-1, also known as Sialoadhesin (Sn) and CD169 is highly conserved among vertebrates and with 17 immunoglobulin-like domains is Siglec-1 the largest member of the Siglec family. Expression of Siglec-1 is found primarily on dendritic cells (DCs), macrophages and interferon induced monocyte. The structure of Siglec-1 is unique among siglecs and its function as a receptor is also different compared to other receptors in this class as it contains the most extracellular domains out of all the siglecs. However, the ability of Siglec-1 to internalize antigens and to pass them on to lymphocytes by allowing dendritic cells and macrophages to act as antigen presenting cells, is the main reason that has granted Siglec-1's key role in multiple human disease states including atherosclerosis, coronary artery disease, autoimmune diseases, cell-cell signaling, immunology, and more importantly bacterial and viral infections. Enveloped viruses for example have been shown to manipulate Siglec-1 to increase their virulence by binding to sialic acids present on the virus glycoproteins allowing them to spread or evade immune response. Siglec-1 mediates dissemination of HIV-1 in activated tissues enhancing viral spread via infection of DC/T-cell synapses. Overall, the ability of Siglec-1 to bind a variety of target cells within the immune system such as erythrocytes, B-cells, CD8+ granulocytes and NK cells, highlights that Siglec-1 is a unique player in these essential processes.","PeriodicalId":14333,"journal":{"name":"International Reviews of Immunology","volume":"42 2","pages":"113-138"},"PeriodicalIF":5.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9459175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Host factors subverted by Mycobacterium tuberculosis: Potential targets for host directed therapy. 结核分枝杆菌破坏宿主因子:宿主定向治疗的潜在靶点。

IF 5 4区医学

International Reviews of Immunology Pub Date : 2023-01-01 DOI: 10.1080/08830185.2021.1990277

Rashi Kalra, Drishti Tiwari, Hedwin Kitdorlang Dkhar, Ella Bhagyaraj, Rakesh Kumar, Anshu Bhardwaj, Pawan Gupta

{"title":"Host factors subverted by Mycobacterium tuberculosis: Potential targets for host directed therapy.","authors":"Rashi Kalra, Drishti Tiwari, Hedwin Kitdorlang Dkhar, Ella Bhagyaraj, Rakesh Kumar, Anshu Bhardwaj, Pawan Gupta","doi":"10.1080/08830185.2021.1990277","DOIUrl":"https://doi.org/10.1080/08830185.2021.1990277","url":null,"abstract":"Introduction: Despite new approaches in the diagnosis and treatment of tuberculosis (TB), it continues to be a major health burden. Several immunotherapies that potentiate the immune response have come up as adjuncts to drug therapies against drug resistant TB strains; however, there needs to be an urgent appraisal of host specific drug targets for improving their clinical management and to curtail disease progression. Presently, various host directed therapies (HDTs) exist (repurposed drugs, nutraceuticals, monoclonal antibodies and immunomodulatory agents), but these mostly address molecules that combat disease progression.Areas covered: The current review discusses major Mycobacterium tuberculosis (M. tuberculosis) survival paradigms inside the host and presents a plethora of host targets subverted by M. tuberculosis which can be further explored for future HDTs. The host factors unique to M. tuberculosis infection (in humans) have also been identified through an in-silico interaction mapping.Expert opinion: HDTs could become the next-generation adjunct therapies in order to counter antimicrobial resistance and virulence, as well as to reduce the duration of existing TB treatments. However, current scientific efforts are largely directed toward combatants rather than host molecules co-opted by M. tuberculosis for its survival. This might drive the immune system to a hyper-inflammatory condition; therefore, we emphasize that host factors subverted by M. tuberculosis, and their subsequent neutralization, must be considered for development of better HDTs.","PeriodicalId":14333,"journal":{"name":"International Reviews of Immunology","volume":"42 1","pages":"43-70"},"PeriodicalIF":5.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9824545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Combining the past and present to advance immuno-radiotherapy of cancer. 结合过去和现在，推进癌症的免疫放疗。

IF 5 4区医学

International Reviews of Immunology Pub Date : 2023-01-01 DOI: 10.1080/08830185.2021.1974020

Ioannis M Koukourakis, Michael I Koukourakis

{"title":"Combining the past and present to advance immuno-radiotherapy of cancer.","authors":"Ioannis M Koukourakis, Michael I Koukourakis","doi":"10.1080/08830185.2021.1974020","DOIUrl":"https://doi.org/10.1080/08830185.2021.1974020","url":null,"abstract":"Since its first clinical application, 120 years ago, radiotherapy evolved into a major anti-cancer treatment modality, offering high cure rates in many human malignancies. During the past ten years, the establishment of immune checkpoint inhibitors (ICIs) in cancer therapeutics has vigorously reintroduced the immune system's role in the outcome of radiotherapy and, conversely, the role of radio-vaccination in the efficacy of immunotherapy. The knowledge and clinical experience that founded the current era of immuno-radiotherapy started alongside with the birth of radiotherapy, and evolved through exhaustive experimental work, clinical trials on active specific immunotherapy, frustrating attempts to validate the importance of cytokine administration with radiotherapy, and, finally, the encouraging ICI-based clinical trials that opened the door to a far more encouraging perspective; radio-vaccination, through its old and new methods, is rising as a research field that promises to cure, previously incurable, disease. In this critical review, we focus on the scientific knowledge gathered through more than a century of research on radiotherapy interactions with the immune system. Understanding the origins of this promising therapeutic approach will substantially contribute to developing new immuno-radiotherapy policies in the fight against cancer.","PeriodicalId":14333,"journal":{"name":"International Reviews of Immunology","volume":"42 1","pages":"26-42"},"PeriodicalIF":5.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9454021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7